Sign In
Buy BOLD
$2.50
+0 (+0%)
At Close: Jul 31, 2026
Boundless Bio, Inc. (BOLD) Upgraded to Buy: Here's Why
01:01pm, Friday, 13'th Feb 2026
Boundless Bio, Inc. (BOLD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Boundless Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
07:00am, Thursday, 05'th Feb 2026
SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to p
Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway
07:00am, Tuesday, 20'th Jan 2026
BBI-940 IND accepted; initiation of first-in-human clinical trial on track for the first half of 2026 Portfolio prioritization, including discontinuation of POTENTIATE trial, extends operating runwa
BUBBA® UNVEILS A BOLD, NEW BRAND IDENTITY AND NEXT-GEN WATER BOTTLE DESIGNS, TURNING EVERYDAY HYDRATION INTO PERSONAL EXPRESSION
07:00am, Wednesday, 14'th Jan 2026
It's Not About the Water, It's About the Drip. bubba®'s New Look, Fashion-forward Finishes, And Bold Colorways, Transform Hydration into a Statement Piece ATLANTA, Jan. 14, 2026 /PRNewswire/ -- Tod
21shares launches BOLD ETP combining bitcoin and gold in a single regulated product
04:00am, Tuesday, 13'th Jan 2026
Approved by Archax 12/01/2026 Don't invest unless you're prepared to lose all the money you invest. This is a high-risk investment and you should not expect to be protected if something goes wrong.
Boundless Bio to Participate in the Piper Sandler 37th Annual Healthcare Conference
07:00am, Monday, 24'th Nov 2025
SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Boundless Bio, (Nasdaq: BOLD) a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to p
Boundless Bio Reports Third Quarter 2025 Financial Results and Business Highlights
07:00am, Wednesday, 05'th Nov 2025
Enrollment ongoing in BBI-355 / BBI-825 combination arm of the POTENTIATE trial Investigational new drug submission for BBI-940 on track, with a first-in-human clinical trial expected to initiate in t
Boundless Bio will be presenting upcoming poster presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
BLOOMINGDALE'S UNVEILS BOLD FALL 2025 CAMPAIGN: JUST IMAGINE
09:00am, Thursday, 04'th Sep 2025
An immersive celebration of art, identity, and modern retail arrives this fall at Bloomingdale's 59th Street flagship—featuring a striking façade and Carousel takeover, designed by acclaimed artist
PRINGLES® IS BRINGING BOLD NEW FLAVORS TO THE SNACK AISLE WITH SIX SMOKY, SALTY AND SWEET INNOVATIONS
08:00am, Monday, 25'th Aug 2025
Introducing New Pringles Smoky lineup, Pringles Sharp White Cheddar, Pringles Mingles Cinnamon & Sugar and Jalapeño & Queso, plus a unique opportunity to give one flavor a first try KEY POINTS: Pring
Boundless Bio (BOLD) Q2 R&D Drops 17%
07:58pm, Tuesday, 05'th Aug 2025
Boundless Bio (BOLD -1.67%), a biotechnology company developing targeted cancer therapies based on extrachromosomal DNA (ecDNA) biology, released its second quarter 2025 results on August 5, 2025. As
Boundless Bio Reports Second Quarter 2025 Financial Results and Business Highlights
07:00am, Tuesday, 05'th Aug 2025
BBI-355 and BBI-825 combination arm of the POTENTIATE trial is now open for enrollment BBI-940 is on track for submission of an investigational new drug application in the first half of 2026 $127 mil
Boundless Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
04:58pm, Thursday, 05'th Jun 2025
SAN DIEGO, June 05, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to p
Boundless Bio Announces Portfolio Prioritization and Runway Extension
04:01pm, Friday, 23'rd May 2025
Portfolio prioritization focuses on novel-novel combination therapy of BBI-355 and BBI-825 and new development candidate, BBI-940, for novel kinesin program
The new limited-edition offering blending the flavors of juicy guava and zesty ginger haspicked up multiple awards before officially hitting shelves in June NEW YORK , May 21, 2025 /PRNewswire/ -- Fro
